Maira Aguiar

Dr. Maira Aguiar

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in Physics of Life Reviews
Verified
Journal Article
Closed access
MAMaira Aguiar
Maira Aguiar
VAVizda Anam
Vizda Anam
KBKonstantin B. Blyuss
Konstantin B. Blyuss
CECarlo Delfin S. Estadilla
Carlo Delfin S. Estadilla
BGBruno V. Guerrero
Bruno V. Guerrero
NSNico Stollenwerk
Nico Stollenwerk

21 December 2016 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MAMaira Aguiar
Maira Aguiar
NSNico Stollenwerk
Nico Stollenwerk
SHScott B. Halstead
Scott B. Halstead
With approximately 3 billion people at risk of acquiring the infection, dengue fever is now considered the most important mosquito-borne viral disease in the world, with 390 million dengue infections occurring every year, of which 96 million manifest symptoms with any level of disease severity. Treatment of uncomplicated dengue cases is only supportive and severe dengue cases require hospital intensive care. A vaccine now licensed in several countries and developed by Sanofi Pasteur (CYD-TDV, named Dengvaxia), was able to protect, in the first 25 months of the two Phase III, 66% of a subset of 9–16 year old participants. However, a significantly lower efficacy (including negative vaccine efficacy) was noted for children younger than 9 years of age. Analysis of year 3 results of phase III trials of Dengvaxia suggest high rates of protection of vaccinated partial dengue immunes but high rates of hospitalizations during breakthrough dengue infections of persons who were vaccinated when seronegative, with vaccine appearing to induce enhancing antibodies (ADE). An age structured model was developed based on Sanofi’s recommendation to vaccinate persons age 945 years in dengue endemic countries. The model was used to explore the clinical burden of two vaccination strategies: 1) Vaccinate 4 or 20% of individuals, ages 9–45 years, seropositives and seronegatives, and 2) vaccinate 4 or 20% of individuals, ages 9–45 years, who are dengue immune only. Our results show that vaccinating dengue monotypic immune individuals prevents dengue hospitalizations, but at the same time dengue infections of vaccine-sensitized persons increases hospitalizations. When the vaccine is given only to partial immune individuals, after immunological screening of the population, disease burden decreases considerably. Caused by four antigenically related but distinct serotypes a tetravalent vaccine is needed to protect against the huge burden of dengue disease. Dengvaxia is a vaccine candidate now licensed in several countries for individuals 9–45 years of age living in endemic countries with at least 50% (preferably 70%) of seroprevalence. Modelers from Sanofi Pasteur have predicted that this vaccine has the potential to reduce by about 50% the disease burden within 5 years when 20% of an endemic country population is vaccinated, thus achieving a World Health Organization dengue prevention goal. In this paper, mathematical modeling is used to investigate the impact of the newly licensed dengue vaccine using different scenarios. Our results show that to achieve significant reduction in disease burden, the vaccination program is most effective if it includes only individuals that have been already exposed to at least one dengue virus. Immunological screening of the population prior to vaccination is advised and vaccination strategies must be planned based on epidemiological disease dynamics for each specific endemic region.


1 August 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
MAMaira Aguiar
Maira Aguiar
NSNico Stollenwerk
Nico Stollenwerk
SHScott B Halstead
Scott B Halstead

4 December 2008 in Mathematical Modelling of Natural Phenomena
Verified
Journal Article
Closed access
PDF file
MAMaira Aguiar
Maira Aguiar
BKBob Kooi
Bob Kooi
NSNico Stollenwerk
Nico Stollenwerk
Basic models suitable to explain the epidemiology of dengue fever have previously shown the possibility of deterministically chaotic attractors, which might explain the observed fluctuations found in empiric outbreak data. However, the region of bifurcations and chaos require strong enhanced infectivity on secondary infection, motivated by experimental findings of antibody-dependent-enhancement. Including temporary cross-immunity in such models, which is common knowledge among field researchers in dengue, we find bifurcations up to chaotic attractors in much wider and also unexpected parameter regions of reduced infectivity on secondary infection, realistically describing more likely hospitalization on secondary infection when the viral load becomes high. The model shows Hopf bifurcations, symmetry breaking bifurcations of limit cycles, coexisting isolas, and two different possible routes to chaos, via the Feigenbaum period doubling and via torus bifurcations.

1 July 2020 in Vaccine
Verified
Journal Article
Closed access
SHScott B Halstead
Scott B Halstead
LKLeah C. Katzelnick
Leah C. Katzelnick
PRPhilip K. Russell
Philip K. Russell
LMLewis Markoff
Lewis Markoff
MAMaira Aguiar
Maira Aguiar
ADAntonio L. Dans
Antonio L. Dans